Stock REPCF REPLICEL LIFE SCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company RepliCel Life Sciences Inc.

Equities

REPCF

CA76027P4006

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 11:20:42 2024-03-15 am EDT 		5-day change 1st Jan Change
0.0428 USD +4.99% Intraday chart for RepliCel Life Sciences Inc. -.--% -4.89%
Apr. 18 RepliCel Life Sciences Inc. Announces Secured Loan Agreement CI
2023 RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Business Summary

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

Number of employees: 1

Sales per Business

CAD in Million2021Weight2022Weight Delta
Cell Replication Technology
100.0 %
0 100.0 % 0 100.0 % -.--%

Sales per region

CAD in Million2021Weight2022Weight Delta
Canada
100.0 %
0 100.0 % 0 100.0 % -.--%

Managers

Managers TitleAgeSince
Andrew Schutte CEO
 Chief Executive Officer 35 18-12-13
Rolf Hoffmann FOU
 Founder 63 -
Kevin McElwee FOU
 Founder 54 -
David Kwok DFI
 Director of Finance/CFO - 23-08-15
David Hall CHM
 Chairman 71 10-12-21
Ben Austring COO
 Chief Operating Officer 41 22-11-27
Robert Buckler BRD
 Director/Board Member 58 14-09-30

Members of the board

Members of the board TitleAgeSince
David Hall CHM
 Chairman 71 10-12-21
Peter Lewis BRD
 Director/Board Member 69 11-05-26
Rolf Hoffmann FOU
 Founder 63 -
Robert Buckler BRD
 Director/Board Member 58 14-09-30
Gary Boddington BRD
 Director/Board Member 56 21-05-31
Andrew Schutte CEO
 Chief Executive Officer 35 18-12-13
Peter Lowry BRD
 Director/Board Member 61 18-12-13
Jamie Mackay BRD
 Director/Board Member - 23-08-08

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,426,772 24,249,871 ( 39.48 %) 0 39.48 %

Shareholders

NameEquities%Valuation
Andrew Schutte
26.77 %
17,401,616 26.77 % 765 671 $
Jamie Mackay
15.44 %
10,034,537 15.44 % 441 520 $
YOFOTO (China) Health Industry Co., Ltd.
8.243 %
5,357,900 8.243 % 235 748 $
MainPointe Pharmaceuticals LLC
6.133 %
3,986,684 6.133 % 175 414 $
Kevin McElwee
2.045 %
1,329,245 2.045 % 58 487 $
Peter Lowry
1.836 %
1,193,426 1.836 % 52 511 $
David Hall
1.347 %
875,632 1.347 % 38 528 $
Peter Lewis
0.9645 %
626,920 0.9645 % 27 584 $
Rolf Hoffmann
0.7532 %
489,572 0.7532 % 21 541 $
Ben Austring
0.4931 %
320,500 0.4931 % 14 102 $
NameEquities%Valuation
Andrew Schutte
27.82 %
303,030 27.82 % 13 333 $
David Hall
4.173 %
45,454 4.173 % 2 000 $
Peter Lewis
4.173 %
45,454 4.173 % 2 000 $

Company contact information

RepliCel Life Sciences, Inc.

570 Granville Street Suite 900

V6C 3P1, Vancouver

+604 248 8730

http://www.replicel.com
address RepliCel Life Sciences Inc.(REPCF)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REPLICEL LIFE SCIENCES INC. Stock RepliCel Life Sciences Inc.
-4.89% 2.78M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.69% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.22% 96.09B
ARGENX SE Stock argenx SE
+2.13% 22.28B
BIONTECH SE Stock BioNTech SE
-16.60% 21.4B
GENMAB A/S Stock Genmab A/S
-8.79% 18.14B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.79% 16.09B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.15% 13.83B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.80% 11.97B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. REPCF Stock
  4. Company RepliCel Life Sciences Inc.